Listen to The Lancet Oncology

Harriet Rumgay (International Agency for Research on Cancer, France) discusses the recent global burden of cancer in 2020 attributable to alcohol consumption study

Doctor Philipp Karschnia (Ludwig-Maximilians-University of Munich, Munich, Germany) discusses the Response Assessment in Neuro Oncology consortium’s recommendations on standardised tissue sampling and processing during resection of diffuse intracranial glioma.

Dr. Wanda Cui (Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia) discusses her Review on measuring ovarian toxicity in clinical trials.

Xuesong Han (American Cancer Society, Atlanta, GA, USA) discusses her study on changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA.

Professor Ian Tannock (Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada) discusses his Policy Review on Common Sense Oncology principles for the design, analysis and reporting of phase 3 randomised clinical trials.

Professor M Saiful Huq (Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, USA) and Dr Mostafa Aziz Sumon (Radiation Oncology, Kurmitola General Hospital, Dhaka, Bangladesh) discuss their Series on Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries.

Dr Hisham Mehanna (University of Birmingham, Birmingham, UK) and Dr Sue Yom (University of California, San Francisco, San Francisco, CA, USA) discuss their four-paper Series on Head and Neck Cancer Consensus Recommendations in diagnosis and clinical trial endpoints.

Professor Mike Sathekge (Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa) discusses his Article entitled, ‘Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre retrospective study.’

Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Professor Abdalla Awidi (Founder and Director of Stem Cell Therapy Center, University of Jordan, Amman, Jordan) to discuss The Lancet Oncology's Cancer control in the Middle East Series. The Series comprises five papers from regional experts who discuss the current outlook for cancer in the Middle East and future developments.

Cheryl Reeves, Senior Editor at The Lancet Oncology, is joined by Professor James Nagarajah to discuss his open-label, randomised, phase 2 study [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE).

Join us for this special episode where Deputy Editor Cheryl Lai speaks with Ali Landman, Editor-in-Chief of The Lancet Medical Imaging & Theranostics, about the scope and vision of the new journal and Ali's highlights in oncological imaging from the European Congress of Radiology in Vienna.

Kayleigh Bhangdia discusses the latest GBD breast cancer study data, telling the audience about epidemiological trends, disease burden, and risk factors associated with breast cancer globally, regionally, and nationally for 204 countries from 1990 to 2023. Kayleigh sheds light on disparities in breast cancer burden across the globe and forecasts to 2050, and highlights the the most critical areas that future GBD studies should focus on to improve the accuracy, relevance, and impact of breast cancer estimates worldwide.

Jamie Prowse, Senior Editor at The Lancet Oncology, is joined by Dr Dylan Graetz and Dr Erica Kaye to discuss qualitative in oncology.

Cheryl Lai, Senior Editor of The Lancet Oncology, is joined by Dr Jesse Plascak and Dr Marissa Baker to discuss their population-based study analysing cancer mortality rates by sex, cancer type, and occupation type among working-age adults in the USA.

Dr Andre Pfob and Prof Peter Dubsky discuss their Review entitled The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer—a multidisciplinary consensus.

Dr Gary Rodin discusses The human crisis in cancer: a Lancet Oncology Commission which identifies a growing imbalance between technological innovation and the human dimensions of cancer care.

Deputy Editor Ali Landman speaks with Matthias Preusser about two reports from the phase 2 TUXEDO-3 trial investigating patritumab deruxtecan (HER3-Dxd) in patients with active brain metastases of breast cancer or non-small-cell lung cancer.

Andrea Necchi, Associate Professor at the Vita-Salute San Raffaele University, discusses his SunRISe4-trial published in our October issue.

Kat Gourd, Acting Deputy Editor of The Lancet Oncology, is joined by Dr Linda Bi, Dr Ruchit Patel, Dr Chloe Gui, Dr Farshad Nassiri, and Dr Matija Snuderl, from institutions in the USA and Canada, to discuss two exciting papers on TERT expression and TERT promoter mutations in meningiomas.

Jinming Li discusses his international, multicohort, observational study on patterns in genomic mutations among patients with early-onset colorectal cancer.

Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Professor Caroline Robert from Gustave Roussy Cancer Campus, France to discuss the EBIN trial on the use of a targeted-therapy induction regimen before treatment with immune checkpoint inhibitors in patients with metastatic melanoma with BRAFV600E or BRAFV600K mutations.

Kat Gourd, Acting Deputy Editor of The Lancet Oncology, is joined by Professor Richard Bryant from the University of Oxford to discuss the TRANSLATE trial on transperineal vs transrectal biopsy for prostate cancer.

Professor Amar U. Kishan (Department of Radiation Oncology, University of California, Los Angeles, CA, USA) discusses his paper on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA): An Individual Patient Data Meta-Analysis of Randomised Trials in the MARCAP Consortium.

Ariana Znaor (Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France) discusses her Review on cancer surveillance in the Eastern Mediterranean Region: a 10-year IARC-WHO EMRO collaboration.

Dr Yannick Romero (Union for International Cancer Control) discusses his Policy Review on the changing landscape of the national cancer control plans and his work with the international cancer control partnership.

Dr Steven Horwitz (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a phase 1 study of valemetostat in relapsed or refractory non-Hodgkin lymphoma and a phase 2 study of valemetostat in relapsed or refractory peripheral T-cell lymphoma.

May Abdel-Wahab (Division of Human Health, Department of Nuclear Science and Applications, International Atomic Energy Agency, Vienna, Austria) and Andrew Scott (Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia) discuss The Lancet Oncology Commission on Radiotherapy and Theranostics.

Dr Zachary Zumsteg (Cedars-Sinai Medical Center, Los Angeles, CA, USA) discusses his Review on the challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations.

Dr Kanwal Raghav (Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his Article entitled, ‘Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a randomised, multicentre, phase 2 trial’.

Dr Emmy Boerrigter (Department of Pharmacy, Radboud University Medical Center, Netherlands) discusses her Review on dose selection of novel anticancer drugs: exposing the gap between selected and required doses.

Dr Garth Strohbehn (Veteran Affairs Center for Clinical Management Research, Ann Arbor, Michigan, USA) and Dr Katie Lichter (University of California, San Francisco, USA) discuss their papers on the environmental impact of cancer treatments and the public harms resulting from it.

Dr James Shultz, (University of Miami Miller School of Medicine, Miami, USA), Dr Ana Patricia Ortiz (University of Puerto Rico, and University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico), and Dr Leticia Nogueira (American Cancer Society, Georgia, USA) discuss their Personal View entitled, ‘Protecting Caribbean patients diagnosed with cancer from compounding disasters.

Dr Bernardo Goulart (US Food and Drug Administration) discusses his paper on correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer.

In a special episode on International Women's Day 2024, we speak with Maria Kyrgiou (Imperial College London, London, UK) about her Essay on innovations and disparities in gynaecological cancer care.

Dr Georgios Lyratzopoulos (University College London, London, UK) discusses his two papers from the International Cancer Benchmarking Partnership on the use of chemotherapy or radiotherapy in eight common cancers in Norway, the UK, Canada, and Australia.

Senior Editor Owen Stretton talks to Professor Shankar Siva from the Peter MacCallum Cancer Centre in Melbourne about the International Society of Stereotactic Radiosurgery’s new systematic review and practice guidelines for stereotactic body radiotherapy in primary renal cell carcinoma.

Professor Neerja Bhatla (All India Institute of Medical Sciences, New Delhi, India) discusses her Article on the Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India.

Dr Chandra Are (University of Nebraska Medical Center, Omaha, NE, USA) discusses highlights and recommendations from the Lancet Oncology Commission on Global Cancer Surgery: pragmatic solutions to improve cancer surgery outcomes worldwide.

Ticiana Leal (Winship Cancer Institute at Emory University, Atlanta, GA, USA) discusses her paper on Tumour Treating Fields.

Carlos Fernández de Larrea (Hospital Clínic de Barcelona, Barcelona, Spain) and Damian Green (Fred Hutch Cancer Center, Seattle, WA, USA) discuss their studies on BCMA CAR T cells in patients with relapsed or refractory multiple myeloma.

Madeline Pe (EORTC, Brussels, Belgium) discusses her Policy Review on the innovative medicines initiative, an expansion of the Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials (SISAQOL) initiative.

Dr Kadia Petricca (SickKids Hospital, Toronto, Canada), Dr Joyce Kambugu (Uganda Cancer Institute, Kampala, Uganda), and Dr Avi Denburg (SickKids Hospital) discuss their paper “Access to essential cancer medicines for children: a comparative mixed-methods analysis of availability, price, and health-system determinants in east Africa”.

Dr Mark Lythgoe (Imperial College London, London, UK), discusses his new Review, "From The European Medicines Agency to Project Orbis: New activities and challenges to facilitate UK Oncology Drug Approval following Brexit".

Prof Janet Brown (University of Sheffield, Sheffield, UK) discusses the phase 2/3 STAR trial on treatment cessation versus continuation with tyrosine kinase inhibitors in advanced renal cell carcinoma.

Prof Valerie Speirs (University of Aberdeen, Aberdeen, Scotland) discusses her Systematic Review on genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers in male breast cancer.

Prof Sameer Bakhshi, (All India Institute of Medical Sciences, New Delhi, India) discusses his Article on sex disparities in childhood cancer in India.

Shankar Siva (Peter MacCallum Cancer Centre, Melbourne, Australia) discusses his Article on 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma.

Mark Lawler (Queen’s University Belfast, Belfast, UK) and Richard Sullivan (Kings College London, London, UK) discuss the European Groundshot—addressing Europe’s cancer research challenges: a Lancet Oncology Commission.

Samar Alhomoud (King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia) discusses her review on progress and remaining challenges for cancer control in the Gulf Cooperation Council.

Inge Marie Svane (Copenhagen University Hospital, Copenhagen, Denmark) discusses her Review on clinical advances and ongoing trials on mRNA vaccines for cancer treatment.